Respiratory syncytial virus vaccines

mresvia

50UG/.5ML For InjectionUnited StatesMarketedAuthorised 31 May 2024

In other countries

The same active substances on other registers, the same brand first.

MresviaCanada · 50 MCG / 0.5 ML · Dispersion · Moderna Biopharma Canada CorporationSame brand
mResviaEuropean Union · Moderna Biotech Spain, S.L.Same brand
MresviaItaly · Dispersione per preparazione iniettabile · Moderna Biotech Spain, S.L.Same brand
mRESVIA dispersie voor injectie in een voorgevulde spuit mRNA-vaccin tegen het respiratoir syncytieel virusNetherlands · Dispersie voor injectie · Moderna Biotech Spain S.L.Same brand
mRESVIA Dispersion for Injection in Pre-Filled Syringe 50mcg/0.5mlSingapore · 0.050mg/0.5ml dose · injection, solution · Moderna Biotech Singapore Pte. LTD.Same brand
AbrysvoItaly · Polvere e solvente per soluzione iniettabile · Pfizer Europe Ma EeigSame form

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Respiratory syncytial virus vaccines

mresvia

50UG/.5ML For InjectionUnited StatesMarketedAuthorised 31 May 2024

Ask Osler about it

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

ArexvyItaly · Polvere e sospensione per sospensione iniettabile · Glaxosmithkline Biologicals S.A.

Arexvy, poeder en suspensie voor suspensie voor injectieNetherlands · Poeder en suspensie voor suspensie voor injectie · GlaxoSmithKline Biologicals S.A.

AREXVY Powder and Suspension for Suspension for Injection 120mcg/0.5mLSingapore · 120mcg/0.5mL · injection, powder, lyophilized, for liposomal suspension · Glaxosmithkline Pte LTD

ArexvyCanada · 120 MCG / 0.5 ML · Powder For Suspension · Glaxosmithkline INC

AbrysvoEuropean Union · Pfizer Europe MA EEIG

ArexvyEuropean Union · GlaxoSmithKline Biologicals S.A.

Arexvy, cjepivo protiv respiratornog sincicijskog virusa (RSV) (rekombinantno, adjuvantirano)Croatia

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

U.S. Food and Drug Administration

FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.

Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions · Added 11 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Respiratory syncytial virus vaccines
Strength: 50UG/.5ML
Dosage form: For Injection
Route: Intramuscular
Register: United States (FDA)
Status: Marketed
Status in the register: Licensed / Rx
Authorised: 31 May 2024
Registration: BLA 125796
Marketing authorisation holder: ModernaTX, Inc.
Procedure: 351(a)
Supply: Rx